摘要关节病性银屑病是一种慢性炎症性关节病变,与该病发病显著相关的易感基因或易感位点有IL-23R、IL-12B、HLA-Cw6、TRAF3IP2、NO、FBXL19、PSMA6-NFKBIA附近区域,可能相关的易感基因有IL-23A、TNIP1、TNF*-857T、LCE3C-LCE3Bdel变异体、REL基因、IL-13.针对关节病性银屑病发病环节中的一些重要免疫分子或免疫细胞,多种靶向生物制剂包括细胞因子拮抗剂(英夫利西、益赛普、阿达木、戈利木、优斯它单抗)、磷酸二酯酶抑制剂、T细胞抑制剂(阿贝西普)和B淋巴细胞耗竭剂(利妥昔单抗)用于该病的治疗,疗效好,安全性较高.

abstractsPsoriatic arthritis is a chronic inflammatory disorder mainly affecting joints.Recent studies have revealed that the development of psoriatic arthritis is associa with many susceptible genes or loci,including interleukin-23 receptor (IL-23R),IL-12B,HLA-Cw6,TRAF3IP2,NO,FBXL19 and PSMA6-NFKBIA nearby,and likely associated with some genes or single nucleotide polymorphisms (SNPs),such as IL-23A,TNIP1,tumor necrosis factor*-857T,LCE3C-LCE3Bdel variant,REL gene and IL-13.Multiple biological agents targeting some key immune molecules or cells in the pathogenesis of psoriatic arthritis have been used to its treatment with a favorable efficacy and safety,including cytokine inhibitors (infliximab,etanercept,adalimumab,golimumab,ustekinumab),phosphodiesterase inhibitors (apremilast),T-cell inhibitors (abatacept),and B lymphocyte-depleting agent (rituximab).